OPRX OptimizeRx Corp

8-K Current Report

Filed: March 5, 2026

Information Technology

Services-Business Services, NEC

OptimizeRx Corp (OPRX) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
3 items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Maturity extended 2 years to Oct 11, 2029, reducing near-term refinancing risk
• Share buyback authorized up to $10M, permitted through Mar 15, 2027 — signals management confidence in valuation

+1 more insights

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 results reported; detailed figures in Exhibit 99.1 press release
• New $10M share repurchase program announced alongside earnings — signals management confidence in valuation

+1 more insights

Item 8.01 · Other Events

• Board authorized $10M share buyback program, effective March 12, 2026, expiring March 15, 2027 or upon full utilization
• Repurchases funded via existing cash/cash equivalents — no new debt or dilution implied

+2 more insights

Get deeper insights on OptimizeRx Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.